Andrew Hodges, MD
Hospitalist · Scottsboro, ALNPI 1265666838
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,234 of the $1,933 with a category attached, or 63.8%. 20 manufacturers reported payments, led by Boston Scientific at 39.5% of the total. Reporting peaked in 2024 at $911 and has fallen 95.4% since, to $42 in 2025. Among hospitalist clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 78 payments — averaging $24.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$764
- Novo Nordisk$313
- AstraZeneca$125
- Lilly USA, LLC$92
- GSK$83
- Pfizer$71
- plus $485 from 14 others
What the payments were for
- Travel & lodging$68836%
- Food & beverage$1,23464%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 5 | $764 |
| Novo Nordisk | 22 | $313 |
| AstraZeneca | 9 | $125 |
| Lilly USA, LLC | 5 | $92 |
| GSK | 5 | $83 |
| Pfizer | 4 | $71 |
| Abbott | 4 | $68 |
| Amgen | 3 | $64 |
| Sanofi-aventis U.S. LLC | 4 | $63 |
| Bayer | 2 | $55 |
| Johnson & Johnson | 3 | $42 |
| Boehringer Ingelheim | 2 | $30 |
| Vifor Pharma, Inc. | 2 | $28 |
| Novartis | 2 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Mylan Specialty L.p. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
How this compares
$1,933 in reported general payments places this provider in the 90th percentile of 265 hospitalist providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 149 | $123,405 |
| OzempicSemaglutide | 92 | $107,448 |
| EliquisApixaban | 109 | $102,540 |
| RybelsusSemaglutide | 56 | $77,925 |
| TrulicityDulaglutide | 65 | $74,464 |
| MounjaroTirzepatide | 47 | $59,876 |
| XareltoRivaroxaban | 44 | $45,581 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 59 | $33,694 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $29,407 |
| JanuviaSitagliptin Phosphate | 39 | $27,060 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $16,704 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $13,107 |
| MyrbetriqMirabegron | 24 | $12,946 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $12,490 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $11,467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $313 | $185,373148 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $92 | $134,340112 claims |
| Boehringer IngelheimJardiance | $30 | $123,405149 claims |
| PfizerEliquis | $71 | $102,540109 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta | $83 | $60,57694 claims |
| Johnson & JohnsonXarelto | $42 | $45,58144 claims |
| Sanofi-aventis U.S. LLCLantus | $63 | $3,16912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 265 hospitalist providers in Alabama.
Other hospitalist in Scottsboro
- Abilash BalmuriAlabaster$6K
- Aftab KhanBirmingham$5K
- Dennis SehgalDecatur$5K
- Neil ShahTuscaloosa$4K
- Mark CromerBirmingham$4K
- Matthew BurdenBirmingham$4K
- Faheem ShaikhBirmingham$3K
- Madhav DevaniHoover$3K
- Kimberly HillmanTuscaloosa$3K
- Sandeep VirkBirmingham$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.